ClinicalTrials.gg
Active, not recruitingNCT07541755PD1-VEN-CAGUpdated Apr 21, 2026

PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL

A Phase 3 interventional study of PD-1 Inhibitors in Acute T Lymphoblastic Leukemia (T-ALL), sponsored by Fujian Medical University Union Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Fujian Medical University Union Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled May 2025, registered Jan 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 27 open to participants now, 28 under way, 4 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
17th of 50
40 · median 30
Started
2025
with 7 others
Phase 3
4 of 51
2 open now
Primary completion
2027-01
later than 14 of 27 live
Registered
48th of 51
by date

Among the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 17th largest by planned enrollment of the 50 interventional ones that give a count, is one of 8 that started in 2025, is one of 4 in phase 3, reaches primary completion later than 14 of the 27 other live ones, and was the 48th registered.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

421 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.

Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

27 of the 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 58 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 23 (40%) set no upper age limit and 30 (52%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

This prospective multicenter study evaluates the efficacy and safety of PD-1 inhibitor combined with venetoclax and HAG/CAG chemotherapy in refractory/relapsed T-ALL (R/R T-ALL). Despite standard chemotherapy, R/R T-ALL remains challenging, with low salvage remission rates (\~40%) and poor survival. Preclinical data suggest PD-1 blockade enhances leukemic stem cell eradication, while venetoclax (BCL-2 inhibitor) synergizes with chemotherapy. Eligible patients receive 1-2 cycles of PD-1 inhibitor + venetoclax + CAG, with responders proceeding to allo-HSCT or MRD-guided consolidation. The trial aims to improve CR rates and survival, offering a novel immunochemotherapy approach for this high-risk population.

Read the detailed description

I. Research Objectives and Background According to the definition and classification by the World Health Organization (WHO), T-cell acute lymphoblastic leukemia (T-ALL) is a precursor lymphoid neoplasm arising from the accumulation of genetic alterations during T-cell development in the thymus, leading to differentiation arrest and abnormal proliferation of immature progenitor cells. It represents a highly heterogeneous group of diseases. The annual incidence of ALL is approximately 1.8 per 100,000 individuals, with T-ALL accounting for about 25% of adult ALL cases.

Despite significant advances in understanding the molecular pathogenesis of T-ALL over the past four decades, its treatment remains predominantly based on standard chemotherapy, which has improved outcomes in newly diagnosed ALL. However, refractory/relapsed T-ALL (R/R T-ALL) still exhibits poor long-term efficacy, with allogeneic hematopoietic stem cell transplantation (allo-HSCT) remaining the primary curative approach. Multiple studies worldwide have confirmed that T-ALL patients achieving remission after intensive chemotherapy still face a high relapse rate. In R/R T-ALL cases, the composite complete remission rate (CRc) following multi-agent salvage chemotherapy remains low (approximately 40%), and the prognosis is dismal. Multivariate analysis of prognostic factors has shown that disease biology (e.g., immunophenotype or cytogenetic abnormalities) does not significantly impact survival in R/R T-ALL. The only predictive factor for long-term survival in this population is whether early salvage therapy is administered. Current international and domestic treatment guidelines recommend clinical trials as the first-line option for R/R ALL patients, including novel drug trials, CAR-T cell therapy targeting various antigens, and investigator-initiated studies (e.g., BCL-2 inhibitor combined with chemotherapy).

Recent pivotal studies have revealed that leukemia stem cells (LSCs) in T-ALL express the immune checkpoint receptor programmed cell death protein 1 (PD-1). Depleting PD-1-expressing cells, genetically deleting PD-1 in T-ALL cells, or blocking PD-1/receptor interactions significantly eradicates LSCs and suppresses disease progression. Combined treatment with PD-1 blockade and chemotherapy markedly prolonged survival in mice transplanted with T-ALL cells. Additionally, venetoclax, an oral selective small-molecule BCL-2 inhibitor, has demonstrated promising efficacy as monotherapy or in combination regimens across various hematologic malignancies. Several studies indicate that T-ALL exhibits sensitivity to venetoclax, and its therapeutic effect can be enhanced when combined with conventional chemotherapeutic agents or targeted therapies.

These findings support the clinical application of PD-1 inhibitor combined with BCL-2 inhibitor (venetoclax) in R/R T-ALL. However, prospective clinical studies are warranted to determine whether this combination can improve outcomes in R/R T-ALL patients.

Based on the above theoretical and clinical evidence, we designed a prospective, multicenter clinical trial for R/R T-ALL patients, evaluating the efficacy and safety of PD-1 inhibitor plus venetoclax combined with HAG regimen (homoharringtonine, cytarabine, and granulocyte colony-stimulating factor). This study aims to enhance overall survival and contribute to the advancement of therapeutic strategies for R/R T-ALL.

II. Study Protocol

Screening Phase:

Patients diagnosed with R/R T-ALL will undergo screening, including bone marrow morphology, immunophenotyping, cytogenetics, fusion gene analysis, and mutation profiling.

Additional assessments: complete blood count, biochemistry, infectious disease screening, chest CT, and ultrasonography (cardiac, lymph node, abdominal). Eligible patients will be enrolled.

Treatment Phase (Cycle 1):

Enrolled patients will receive one course of PD-1 inhibitor + venetoclax + CAG regimen (cytarabine, aclarubicin, granulocyte colony-stimulating factor).

Efficacy evaluation will be performed at \~4 weeks post-treatment.

Response-Adapted Therapy:

Patients achieving morphologic CR with incomplete hematologic recovery (mCRc): Proceed to allo-HSCT as soon as possible. Repeat the regimen if transplant is delayed.

Patients achieving partial remission (PR): Administer a second cycle of PD-1 inhibitor + venetoclax + CAG, followed by re-evaluation at \~4 weeks.

If mCRc is achieved: Proceed to allo-HSCT.

If mCRc is not achieved: Discontinue study treatment and switch to alternative therapies.

Maintenance and Follow-up:

Patients in remission but ineligible for allo-HSCT will continue the regimen until minimal residual disease (MRD)-negative status is achieved, followed by two additional cycles of PD-1 inhibitor + CAG before entering the follow-up phase.

03

Conditions studied

  • Acute T Lymphoblastic Leukemia (T-ALL)

Keywords

  • acute T-lymphoblastic leukemia
  • PD-1 inhibitor
  • CAG
  • venetoclax
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >=18 years old;
  2. Met the T-ALL diagnosis before enrollment (for specific diagnostic criteria, see the attachment);
  3. T-ALL (newly diagnosed T-ALL that fails to achieve remission after treatment with one standard regimen) or recurrent T-ALL (bone marrow blasts exceed 5% again after remission, and the morphology and immunophenotype of leukemia cells are consistent with T-ALL);
  4. The performance status score of the (ECOG) in the United States ranges from 0 to 2 points.
  5. Expected survival period >=3 months;
  6. During the screening period, there were no organ function abnormalities that restricted the use of this scheme.
  7. Understand this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with /relapsed T-ALL who are not suitable for or whose economic conditions restrict the use of and venetoclax for treatment;
  2. Diseases that may limit patients' participation in this trial due to abnormal functions of organs such as the heart, lungs, liver, and kidneys (such as advanced infections, uncontrolled diabetes, severe heart failure or angina pectoris, active pulmonary tuberculosis, asthma, , bronchiectasis, severe renal insufficiency, etc.);
  3. There has been a history of other malignant tumors within the past five years;
  4. Known infection, active virus (HbsAg positive and HBV-DNA higher than the upper limit of the detection value) or active virus (anti-HCV antibody positive or HCV RNA positive) infection;
  5. Inability to understand or comply with the research protocol;
  6. Patients under 18 years old.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    PD-1+venetoclax+CAG treatment group

    PD-1 inhibitor combined with venetoclax and CAG regimen (cytarabine, aclarubicin, G-CSF) for up to 2 cycles of 21 days each in patients with relapsed/refractory T-ALL.

    Drug: PD-1 Inhibitors

Interventions

06

What researchers measure

Primary outcomes

  1. mCRc

    CR+CRi+MLFS

    Time frame: At the end of Cycle 2 (each cycle is 21 days)

Secondary outcomes

  1. Overall survival

    Time frame: After 2 years

  2. Side effect

    Hematological and non-hematological adverse reactions

    Time frame: At the end of every Cycle (each cycle is 21 days)

  3. minimal residual disease, MRD

    Time frame: At the end of every Cycle (each cycle is 21 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The anonymized raw data generated in this study will be shared within six months after the publication of the main research results. The shared data include baseline characteristics of the subjects, efficacy evaluation results and safety data. The data will be provided through the following channels: 1. Public database: Upload to the "Results" section of ClinicalTrials.gov. 2. On-demand application: Researchers can contact the corresponding author by email, submit the research plan and data usage agreement, and obtain the data after approval by the ethics committee. The use of data must meet the following conditions: - Only for non-commercial academic research; Do not attempt to identify the identity of the subjects; When citing data, the source must be indicated.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Within 6 months after the publication of the main results.

Access criteria: Data will be accessible through two channels: (1) Publicly available in the "Results" section of ClinicalTrials.gov; (2) Upon reasonable request to the corresponding author. For channel (2), researchers must submit a research plan and data use agreement. Access is granted after approval by the ethics committee. Data use is restricted to non-commercial academic research. Users must not attempt to identify participants and must cite the source.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Jan 2027, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Apr 21, 2026
StartActual
May 1, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2029
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07541755
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 1, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Apr 21, 2026

Study contacts

Shaoyuan Wang, Pro
principal investigator · Fujian Institute of Hematology,Fujian Provincial Key Laboratory on Hematology,Fujian Medical University Union Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immune checkpoint inhibitors

Start the discussion